Interstitial pneumonia
Conditions
Interventions
None listed
Sponsors
Division of Respiratory Medicine and Clinical Allergy,Fujita Health University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible patients are men and women aged 75 years or older with interstitial pneumonia in initial chest HRCT.
Exclusion criteria
Exclusion criteria: Patients who have malignant tumor, defined connective tissue disease, occupational and/or environmental exposure that resulted in interstitial pneumonia, or drug induced interstitial pneumonia are excluded from this study. Patient who have already used home oxygen therapy at first visit are also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference of progression free survival (PFS) in each group. Definition of progression is 10% < decline of %FVC or 15% < decline of DLCO compared with initial pulmonary function test, the introduction of home oxygen therapy, more than 90days hospitalization due to irreversible worsening of respiratory status, or death. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are the changes of Modified Medical Research Council Dyspnea Scale, percutaneous oxygen saturation, partial pressure of oxygen in arterial blood, vital capacity, forced vital capacity, the distance and minimum SPO2 of 6 minutes walk test, KL-6/SP-D, Overall Survival. | — |
Countries
Japan
Contacts
Public ContactTomoyuki Minezawa
Fujita Health University School of Medicine Division of Respiratory Medicine and Clinical Allergy
Outcome results
None listed